PMID: 2510050Oct 1, 1989Paper

Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin

Neuropharmacology
A UekiC D Marsden

Abstract

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), or 0.9% saline, was administered to a group of common marmosets initially treated with the toxin 12-18 months previously. Initial treatment had consisted of a cumulative dose of 6-22 mg/kg (i.p.) which caused marked parkinsonism. Subsequently, the animals gradually recovered normal motor function. Further treatment consisted of a cumulative dose of MPTP of 78-83 mg/kg (i.p.) but this produced only modest akinesia. At 12-18 months after the initial treatment with MPTP, the content of dopamine, HVA and DOPAC in the caudate and putamen was markedly reduced. However, levels of dopamine, HVA and DOPAC in the nucleus accumbens were normal. Three months after the second treatment with MPTP there was no further decrease in the content of dopamine in the caudate-putamen. However, in the nucleus accumbens the content of dopamine, HVA and DOPAC was now reduced. The initial treatment with MPTP substantially decreased the binding of [3H]mazindol in the caudate-putamen but less so in the nucleus accumbens. Only a small additional decrease occurred upon further treatment with MPTP. The density of tyrosine hydroxylase (TH) immunoreactive cells in substantia nigra was reduced after the initia...Continue Reading

References

Oct 1, 1986·Annals of Neurology·L S FornoG A Ricaurte
Aug 1, 1986·Neuropharmacology·A J BradburyR J Naylor
May 16, 1985·Biochemical and Biophysical Research Communications·K ChibaN Castagnoli
Dec 16, 1985·Brain Research·E MelamedM Globus

❮ Previous
Next ❯

Citations

Sep 29, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·S A TresederP Jenner
Jan 1, 1995·Journal of Neural Transmission. General Section·K K GnanalinghamC D Marsden
Jan 1, 1994·Molecular and Chemical Neuropathology·M E Emborg, J A Colombo
Jan 12, 1993·European Journal of Pharmacology·S RoseC D Marsden
Dec 12, 1991·European Journal of Pharmacology·M GerlachM B Youdim
Sep 5, 1998·Brain Research. Brain Research Reviews·G L Willis, S M Armstrong
Aug 23, 2007·ILAR Journal·Marina E Emborg
Aug 1, 1990·Pharmacology & Toxicology·S Kaakkola, H Teräväinen
May 25, 2006·Cell Transplantation·Paul M CarveyMary B Newman
Sep 15, 2018·Behavioural Pharmacology·Adjia HamadjidaPhilippe Huot
Apr 4, 2019·Chemistry : a European Journal·Shona BanjoNoritaka Chida
Oct 19, 2000·Neuropathology : Official Journal of the Japanese Society of Neuropathology·P L Lantos, N Nakamura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.